Bioasis to Present at Investor & Industry Conferences in January 2019
December 13 2018 - 4:30PM
Business Wire
Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the
“Company” or “Bioasis”), a pre-clinical,
research-stage biopharmaceutical company developing its
proprietary xB3™ platform technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and
the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases, today
announced that members of management will present at the following
investor and industry conferences in January 2019:
2nd Annual Neuroscience Innovation Forum
- Mark Day, Ph.D., director, president
and chief executive officer will deliver the Bioasis company
presentation at the 2nd Annual Neuroscience Innovation Forum on
Mon., Jan. 6, 2019 at 12:05 p.m. PT in the Heritage Room at
the Marines' Memorial Club & Hotel, San Francisco.
- Dr. Mark Day will also co-chair the
Advances in Rare & Orphan Diseases panel on Mon.,
Jan. 6 at 2:10 p.m. PT.
Biotech Showcase™
- Dr. Mark Day will deliver the Bioasis
company presentation at Biotech Showcase on Tues., Jan 7, 2019 at
10 a.m. PT in the Yosemite C Ballroom at the Hilton San Francisco
Union Square, San Francisco.
PepTalk - The Protein Science Week
- Mei Mei Tian, Ph.D., vice president,
head of external research will present, "The xB3 Platform
Delivers a Protein-Based Interleukin 1 Receptor Antagonist across
the BBB and Ameliorates Neuropathic Pain in a Preclinical Model" at
PepTalk – The Protein Science Week on Mon., Jan. 14, 2019 at 11:45
a.m. PT at the Hilton San Diego Bayfront, San Diego.
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Mark Day, Ph.D., Director, President & Chief Executive
Officer
ABOUT BIOASIS
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3™ platform, a proprietary technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and
the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the BBB represents the final
frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181213005774/en/
Bioasis Technologies, Inc.Catherine
London+1-917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024